DS-2325a + DS-2325a + Placebo + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Netherton Syndrome
Conditions
Netherton Syndrome
Trial Timeline
Jun 20, 2022 → Jan 26, 2023
NCT ID
NCT05388903About DS-2325a + DS-2325a + Placebo + Placebo
DS-2325a + DS-2325a + Placebo + Placebo is a phase 1 stage product being developed by Daiichi Sankyo for Netherton Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT05388903. Target conditions include Netherton Syndrome.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05388903 | Phase 1 | Completed |
Competing Products
8 competing products in Netherton Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DS-2325a | Daiichi Sankyo | Phase 1/2 | 24 |
| DS-2325a + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| Pimecrolimus 1% Cream | Novartis | Phase 1/2 | 32 |
| BCX17725 + Placebo | BioCryst Pharmaceuticals | Phase 1 | 30 |
| QRX003-2% Lotion + QRX003-4% Lotion QAM + Vehicle + QRX003-4% Lotion BID | Quoin Pharmaceuticals | Phase 2/3 | 32 |
| QRX003, 4% Lotion | Quoin Pharmaceuticals | Phase 2/3 | 35 |
| QRX003, 4% Lotion | Quoin Pharmaceuticals | Phase 2/3 | 35 |
| ATR12-351 | Azitra | Phase 1 | 26 |